



SLOVENSKI STANDARD

oSIST prEN ISO 11137-2:2026

01-oktober-2026

Sterilizacija izdelkov za zdravstveno nego - Sevanje - 2. del: Določanje odmerka sterilizacije (ISO/DIS 11137-2:2026)

Sterilization of health care products - Radiation - Part 2: Establishing the sterilization dose (ISO/DIS 11137-2:2026)

Sterilisation von Produkten für die Gesundheitsfürsorge - Strahlen - Teil 2: Festlegung der Sterilisationsdosis (ISO/DIS 11137-2:2026)

Stérilisation des produits de santé - Irradiation - Partie 2: Établissement de la dose stérilisante (ISO/DIS 11137-2:2026)

Ta slovenski standard je istoveten z: **prEN ISO 11137-2**

ICS:

11.080.01	Sterilizacija in dezinfekcija na splošno	Sterilization and disinfection in general
-----------	--	---

oSIST prEN ISO 11137-2:2026

en,fr,de

Sample Document

get full document from standards.iteh.ai



DRAFT International Standard

ISO/DIS 11137-2

Sterilization of health care products — Radiation — Part 2: Establishing the sterilization dose

*Stérilisation des produits de santé — Irradiation —
Partie 2: Établissement de la dose stérilisante*

ICS: 11.080.01

ISO/TC 198

Secretariat: **ANSI**

Voting begins on:
2026-08-14

Voting terminates on:
2026-11-06

This document has not been edited by the ISO Central Secretariat.

ISO/CEN PARALLEL PROCESSING

Reference number
ISO/DIS 11137-2:2026(en)

THIS DOCUMENT IS A DRAFT CIRCULATED FOR COMMENTS AND APPROVAL. IT IS THEREFORE SUBJECT TO CHANGE AND MAY NOT BE REFERRED TO AS AN INTERNATIONAL STANDARD UNTIL PUBLISHED AS SUCH.

IN ADDITION TO THEIR EVALUATION AS BEING ACCEPTABLE FOR INDUSTRIAL, TECHNOLOGICAL, COMMERCIAL AND USER PURPOSES, DRAFT INTERNATIONAL STANDARDS MAY ON OCCASION HAVE TO BE CONSIDERED IN THE LIGHT OF THEIR POTENTIAL TO BECOME STANDARDS TO WHICH REFERENCE MAY BE MADE IN NATIONAL REGULATIONS.

RECIPIENTS OF THIS DRAFT ARE INVITED TO SUBMIT, WITH THEIR COMMENTS, NOTIFICATION OF ANY RELEVANT PATENT RIGHTS OF WHICH THEY ARE AWARE AND TO PROVIDE SUPPORTING DOCUMENTATION.

© ISO 2026

Sample Document

get full document from standards.iteh.ai



COPYRIGHT PROTECTED DOCUMENT

© ISO 2026

All rights reserved. Unless otherwise specified, or required in the context of its implementation, no part of this publication may be reproduced or utilized otherwise in any form or by any means, electronic or mechanical, including photocopying, or posting on the internet or an intranet, without prior written permission. Permission can be requested from either ISO at the address below or ISO's member body in the country of the requester.

ISO copyright office
CP 401 • Ch. de Blandonnet 8
CH-1214 Vernier, Geneva
Phone: +41 22 749 01 11
Email: copyright@iso.org
Website: www.iso.org

Published in Switzerland

ISO/DIS 11137-2:2026(en)

Contents

Page

Foreword	vi
Introduction	viii
1 Scope	1
2 Normative references	1
3 Terms and definitions	1
3.1 Terms and definitions	1
3.2 Abbreviated terms	3
4 Definition of product families for dose setting, dose substantiation and sterilization dose auditing	4
4.1 General	4
4.2 Defining product families	4
4.3 Designation of product to represent a product family	5
4.3.1 Product to represent a product family	5
4.3.2 Master product	5
4.3.3 Equivalent product	6
4.3.4 Simulated product	6
4.4 Maintaining product families	6
4.4.1 Periodic review	6
4.4.2 Aspects of periodic review	6
4.4.3 Evaluation for adoption of new or modified product into a product family	8
4.4.4 Methods for adoption of product into a product family	8
4.4.5 Records	9
4.5 Consequence of failure of sterilization dose establishment or sterilization dose audit	9
5 Selection and testing of product for establishing the sterilization dose	9
5.1 Nature of product	9
5.2 Sample item portion (SIP)	10
5.3 Manner of sampling	11
5.4 Microbiological testing	11
5.5 Irradiation	12
6 Methods of dose establishment	12
7 Method 1: dose setting using bioburden information	13
7.1 Rationale	13
7.2 Procedure for Method 1 for product with an average bioburden greater than or equal to 1,0 for multiple production batches	14
7.2.1 General	14
7.2.2 Stage 1: Select SAL and obtain samples of product	14
7.2.3 Stage 2: Determine average bioburden	14
7.2.4 Stage 3: Obtain verification dose	15
7.2.5 Stage 4: Perform verification dose experiment	15
7.2.6 Stage 5: Interpretation of results	15
7.2.7 Stage 6: Establish sterilization dose	16
7.3 Procedure for Method 1 for product with an average bioburden greater than or equal to 1,0 for a single production batch	16
7.3.1 Rationale	16
7.4 Procedure for Method 1 for product with an average bioburden in the range 0,1 to 0,9 for multiple or single production batches	16
8 Method 2: Dose setting using fraction positive information from incremental dosing to determine an extrapolation factor	17
8.1 Rationale	17
8.1.1 General	17
8.1.2 Modified Method 2	17
8.1.3 Method 2 and Modified Method 2	18

ISO/DIS 11137-2:2026(en)

8.1.4	Bioburden determination.....	18
8.1.5	Calculations.....	18
8.2	Procedure for Method 2A and Modified Method 2A.....	19
8.2.1	General.....	19
8.2.2	Stage 1: Select SAL and obtain samples of product.....	19
8.2.3	Stage 2: Perform bioburden testing and incremental dose experiment.....	19
8.2.4	Stage 3: Perform verification dose experiment.....	22
8.2.5	Stage 4: Interpretation of results.....	22
8.2.6	Stage 5: Establish sterilization dose.....	23
8.3	Procedure for Method 2B and Modified Method 2B.....	23
8.3.1	General.....	23
8.3.2	Stage 1: Select SAL and obtain samples of product.....	24
8.3.3	Stage 2: Perform bioburden testing and incremental dose experiment.....	24
8.3.4	Stage 3: Perform verification dose experiment.....	27
8.3.5	Stage 4: Interpretation of results.....	27
8.3.6	Stage 5: Establish sterilization dose.....	27
9	Method VD_{max}^{SD} — Substantiation of a selected sterilization dose	28
9.1	Selected doses and rationale.....	28
9.2	Procedure for Method VD_{max}^{SD} for multiple production batches.....	29
9.2.1	General.....	29
9.2.2	Stage 1: Obtain samples of product.....	29
9.2.3	Stage 2: Determine average bioburden.....	29
9.2.4	Stage 3: Obtain the selected sterilization dose.....	30
9.2.5	Stage 4: Obtain VD_{max}^{SD}	31
9.2.6	Stage 5: Perform verification dose experiment.....	31
9.2.7	Stage 6: Interpretation of results.....	32
9.2.8	Confirmatory verification dose experiment.....	33
9.3	Procedure for Method VD_{max}^{SD} for a single production batch.....	34
9.3.1	Rationale.....	34
10	Maintaining process effectiveness	34
10.1	General.....	34
10.2	Frequency of determination of bioburden.....	34
10.3	Sterilization dose audit.....	34
10.3.1	Frequency.....	34
10.3.2	Outcome.....	35
10.3.3	Procedure for auditing a sterilization dose established using Method 1, Method 2A, Method 2B, Modified Method 2A and Modified Method 2B.....	35
10.3.4	Augmentation of sterilization dose established using Method 1, Method 2A, or Method 2B.....	38
10.4	Procedure for auditing a sterilization dose substantiated using Method VD_{max}^{SD}	39
10.4.1	General.....	39
10.4.2	Stage 1: Obtain samples of product.....	39
10.4.3	Stage 2: Determine average bioburden.....	39
10.4.4	Stage 3: Perform verification dose experiment.....	40
10.4.5	Stage 4: Interpretation of results.....	40
10.4.6	Confirmatory sterilization dose audit.....	41
10.4.7	Augmentation of a sterilization dose substantiated using Method VD_{max}^{SD}	43
10.5	Failure of a sterilization dose audit.....	44
Annex A (normative)	Method 1 and Method VD_{max}^{SD} verification dose and dose augmentation value tables	45
Annex B (informative)	Worked examples	61
Annex C (informative)	Addressing sterilization dose audit positives	78
Annex D (informative)	Bioburden less than the limit of detection (LOD)	85
Annex E (informative)	Guidance on bioburden alert and action levels	89
Annex F (informative)	Guidance on sample size and microbiological controls	92

ISO/DIS 11137-2:2026(en)

Annex G (informative) Guidance on selection of dose establishment method	94
Annex H (informative) Product adoption worksheet example	96
Annex ZA (informative) Relationship between this European Standard and the General Safety and Performance Requirements of Regulation (EU) 2017/745 aimed to be covered	98
Annex ZB (informative) Relationship between this European Standard and the General Safety and Performance Requirements of Regulation (EU) 2017/746 aimed to be covered	102
Bibliography	105

Sample Document

get full document from standards.iteh.ai

ISO/DIS 11137-2:2026(en)

Foreword

ISO (the International Organization for Standardization) is a worldwide federation of national standards bodies (ISO member bodies). The work of preparing International Standards is normally carried out through ISO technical committees. Each member body interested in a subject for which a technical committee has been established has the right to be represented on that committee. International organizations, governmental and non-governmental, in liaison with ISO, also take part in the work. ISO collaborates closely with the International Electrotechnical Commission (IEC) on all matters of electrotechnical standardization.

The procedures used to develop this document and those intended for its further maintenance are described in the ISO/IEC Directives, Part 1. In particular, the different approval criteria needed for the different types of ISO documents should be noted. This document was drafted in accordance with the editorial rules of the ISO/IEC Directives, Part 2 (see www.iso.org/directives).

ISO draws attention to the possibility that the implementation of this document may involve the use of (a) patent(s). ISO takes no position concerning the evidence, validity or applicability of any claimed patent rights in respect thereof. As of the date of publication of this document, ISO had not received notice of (a) patent(s) which may be required to implement this document. However, implementers are cautioned that this may not represent the latest information, which may be obtained from the patent database available at www.iso.org/patents. ISO shall not be held responsible for identifying any or all such patent rights.

Any trade name used in this document is information given for the convenience of users and does not constitute an endorsement.

For an explanation of the voluntary nature of standards, the meaning of ISO specific terms and expressions related to conformity assessment, as well as information about ISO's adherence to the World Trade Organization (WTO) principles in the Technical Barriers to Trade (TBT), see www.iso.org/iso/foreword.html.

This document was prepared by Technical Committee ISO/TC 198, *Sterilization of health care products*.

This fourth edition cancels and replaces the third edition (ISO 11137-2:2013), which has been technically revised.

The main changes are as follows:

- Method VD_{max}^{SD} tables (i.e. 17,5 kGy, 20 kGy, 22,5 kGy, 27,5 kGy, 30 kGy, 32,5 kGy, and 35 kGy) from ISO 13004 were incorporated and [Table 7](#) was added to describe the different sterilization doses and corresponding upper limit of average bioburden;
- Method VD_{max}^{SD} procedures were combined into one procedure rather than having separate procedures for each sterilization dose;
- VD_{max}^{SD} tables for 15 kGy, 17,5 kGy, 20 kGy, 22,5 kGy, and 25 kGy were all combined into one table, and for 27,5 kGy, 30 kGy, 32,5 kGy, and 35 kGy were all combined into a second table, and both updated tables were added into (normative) [Annex A](#);
- VD_{max}^{SD} tables for dose augmentation values were also combined as described above and added into [Annex A](#);
- VD_{max}^{SD} tables were truncated at average bioburden counts greater than 9,0 CFU to shorten the tables;
- Method 1 tables were moved to [Annex A](#);
- information on maintaining product families, including product review considerations and product adoption from AAMI TIR35 was incorporated;
- information on bioburden limit of detection (LOD) and TNTC/spreaders was added in [Clauses 5, 7, 9, 10](#), and [Annex D](#);
- dose establishment method procedures (Method 1 and Method VD_{max}^{SD}) for a single batch were simplified to contain only the changes that need to be made to the multiple batch procedure when establishing dose for a single batch;

ISO/DIS 11137-2:2026(en)

- information on a Modified Method 2 option from AAMI TIR40 was incorporated;
- information was added to allow continued use of the augmented verification and sterilization doses in Methods 1, 2A, or 2B;
- worked examples were moved to [Annex B](#);
- guidance on sterilization dose audit failures was added in [Annex C](#);
- guidance on bioburden alert and action levels was added in [Annex E](#);
- guidance on sample size and microbiological controls was added in [Annex F](#);
- guidance on selection of dose establishment method was added in [Annex G](#);
- an example product adoption worksheet was added in [Annex H](#).

A list of all parts in the ISO 11137 series can be found on the ISO website.

Any feedback or questions on this document should be directed to the user's national standards body. A complete listing of these bodies can be found at www.iso.org/members.html.

Sample Document

get full document from standards.iteh.ai

ISO/DIS 11137-2:2026(en)

Introduction

This part of ISO 11137 describes methods that can be used to establish the sterilization dose in accordance with one of the two approaches specified in ISO 11137-1:2025, 8.2. The methods used in these approaches are:

- dose setting to obtain a product-specific dose;
- dose substantiation to verify a preselected dose.

The basis of the dose setting methods described in this part of ISO 11137 (Methods 1 and 2) owe much to the ideas first propounded by Tallentire [18][19][20]. Subsequently, standardized protocols were developed (see References [8], [9]), which formed the basis of the dose setting methods detailed in the AAMI Recommended Practice for Sterilization by Gamma Radiation¹⁾ and ANSI/AAMI ST32²⁾.

Methods 1 and 2 and the associated sterilization dose audit procedures use data derived from the inactivation of the microbial population in its natural state on product. The methods are based on a probability model for the inactivation of microbial populations. The probability model, as applied to bioburden made up of a mixture of various microbial species, assumes that each such species has its own unique D_{10} value. In the model, the probability that an item will possess a surviving microorganism after exposure to a given dose of radiation is defined in terms of the initial number of microorganisms on the item prior to irradiation and the D_{10} values of the microorganisms. The methods involve performance of tests of sterility on product items that have received doses of radiation lesser than the sterilization dose. The outcome of these tests is used to predict the dose needed to achieve a predetermined sterility assurance level (SAL).

A modification to Method 2 is provided that reduces the number of incremental doses needed to determine the minimum dose required to achieve a predetermined SAL. The Modified Method 2 can be employed at any time but is more successful when the product bioburden counts and resistance are low.

Methods 1 and 2 can also be used to substantiate any of the VD_{max}^{SD} doses if, on performing a dose setting exercise, the derived sterilization dose for the selected SAL is less than or equal to the selected sterilization dose. The basis of the method devised specifically for substantiation of 25 kGy, Method VD_{max} , was put forward by Kowalski and Tallentire.[14] Subsequent evaluations involving computational techniques demonstrated that the underlying principles were soundly based [13] and field trials confirmed that Method VD_{max}^{SD} is effective in substantiating a selected sterilization dose for a wide variety of products manufactured and assembled in different ways [16].

Method VD_{max}^{SD} is founded on dose setting Method 1 and, as such, it possesses the high level of conservativeness characteristic of Method 1. In a similar manner to the dose setting methods, it involves performance of tests of sterility on product items that have received a specified dose of radiation lesser than the sterilization dose. The outcomes of these tests are used to substantiate that the selected sterilization dose achieves the selected SAL.

To link the use of Method VD_{max} for the substantiation of a particular preselected sterilization dose, the numerical value of the latter, expressed in kiloGrays, is included as a superscript to the VD_{max} symbol. Thus, for substantiation of a sterilization dose of 25 kGy, the method is designated Method VD_{max}^{25} . Reference to the general term of the VD_{max} method but not to a selected sterilization dose is designated VD_{max}^{SD} .

This part of ISO 11137 also describes methods that can be used to carry out sterilization dose audits in accordance with ISO 11137-1:2025, Clause 12. Following establishment of the sterilization dose, sterilization dose audits are performed routinely to confirm that the sterilization dose continues to achieve the desired SAL.

1) Withdrawn.

2) Withdrawn.

Sterilization of health care products — Radiation —

Part 2: Establishing the sterilization dose

1 Scope

This document specifies methods for determining the minimum dose needed to achieve a specified requirement for sterility and methods to substantiate the use of a specified sterilization dose to achieve an SAL of 10^{-6} . This document also specifies methods of sterilization dose audit used to demonstrate the continued effectiveness of the sterilization dose.

This document defines product families for sterilization dose establishment and sterilization dose audit.

2 Normative references

The following documents are referred to in the text in such a way that some or all of their content constitutes requirements of this document. For dated references, only the edition cited applies. For undated references, the latest edition of the referenced document (including any amendments) applies.

ISO 11137-1:2025, *Sterilization of health care products — Radiation — Part 1: Requirements for the development, validation and routine control of a sterilization process for medical devices*

ISO 11737-1:2018, *Sterilization of health care products — Microbiological methods — Part 1: Determination of a population of microorganisms on products*

ISO 11737-2, *Sterilization of health care products — Microbiological methods — Part 2: Tests of sterility performed in the definition, validation and maintenance of a sterilization process*

3 Terms and definitions

For the purposes of this document, the terms and definitions given in ISO 11137-1 and the following apply.

ISO and IEC maintain terminology databases for use in standardization at the following addresses:

- ISO Online browsing platform: available at <https://www.iso.org/obp>
- IEC Electropedia: available at <https://www.electropedia.org/>

3.1 Terms and definitions

3.1.1

action level

value from monitoring that necessitates immediate intervention

[SOURCE: ISO 11139:2018, 3.5]

3.1.2

alert level

value from monitoring providing early warning of deviation from specified conditions

[SOURCE: ISO 11139:2018, 3.11]

ISO/DIS 11137-2:2026(en)**3.1.3****batch**

defined quantity of a product intended or purported to be uniform in character and quality produced during a specified cycle of manufacture

[SOURCE: ISO 11139:2018, 3.21]

3.1.4**candidate product**

product being examined for adoption into an existing product family

3.1.5**false positive**

test result interpreted as growth arising from the product, or portions thereof, tested when either growth resulted from extraneous microbial contamination or turbidity occurred from interaction between the product, or portions thereof, and the test medium

3.1.6**fraction positive**

quotient in which the number of positive tests of sterility is given by the numerator, and the number of tests performed is given by the denominator

[SOURCE: ISO 11139:2018, 3.122]

3.1.7**incremental dose**

dose within a series of doses applied to a number of product, or portions thereof, and used in a dose setting method to obtain or confirm the sterilization dose

[SOURCE: ISO 11139:2018, 3.138]

3.1.8**packaging system**

combination of a sterile barrier system and protective packaging

[SOURCE: ISO 11139:2018, 3.192]

3.1.9**positive test of sterility**

test result for which there is detectable microbial growth from product, or portions thereof, subjected to a test of sterility

3.1.10**sample item portion****SIP**

specified portion of a health care product that is tested

[SOURCE: ISO 11139:2018, 3.240]

3.1.11**standard distribution of resistances****SDR**

reference set of resistances of microorganisms and corresponding probabilities of occurrence

[SOURCE: ISO 11139:2018, 3.263]

3.1.12**sterilization dose audit**

exercise undertaken to confirm the appropriateness of an established sterilization dose

[SOURCE: ISO 11139:2018, 3.281]

ISO/DIS 11137-2:2026(en)

3.2 Abbreviated terms

3.2.1

A

dose to adjust the median ffp dose downwards to the FFP dose

3.2.2

CD*

number of positive tests of sterility obtained from tests performed individually on 100 product items irradiated in a Method 2 verification dose experiment

3.2.3

d*

dose derived from an incremental dose experiment performed on product items drawn from a given production batch

3.2.4

D*

initial estimate of the dose to provide an SAL of 10^{-2} for the test items

Note 1 to entry: Generally, it is the median of the three d^* values derived for a given product.

3.2.5

D**

final estimate of the dose to provide an SAL of 10^{-2} for the test items, which is used in the calculation of the sterilization dose

3.2.6

DD*

highest dose delivered in a Method 2 verification dose experiment

3.2.7

DS

estimate of the D_{10} value of microorganisms present on product after exposure to DD^*

3.2.8

D value **D_{10} value**

time or dose required under stated conditions to achieve inactivation of 90 % of a population of the test microorganism

Note 1 to entry: For the purposes of this part of ISO 11137, D_{10} applies to the radiation dose only and not to time.

[SOURCE: ISO 11139:2018, 3.75, modified — Note to entry has been added.]

3.2.9

first fraction positive dose**ffp**

lowest dose of an incremental dose series, applied to product items drawn from a given production batch, at which at least one of the associated 20 tests of sterility is negative for growth

Note 1 to entry: Notation in lower case refers to results derived from product taken from a single batch.

3.2.10

First Fraction Positive dose**FFP**

dose at which 19 positives out of the 20 tests of sterility are expected to occur, calculated by subtracting A from the median of three ffp doses

Note 1 to entry: Notation in upper case refers to results derived from product taken from all three batches.

ISO/DIS 11137-2:2026(en)

3.2.11**First No Positive dose****FNP**

estimate of the dose to provide an SAL of 10^{-2} for the test items, that is used in the calculation of *DS*

3.2.12 **$VD_{\max}^{SD}$**

maximal verification dose for a given bioburden, consistent with the attainment of an SAL of 10^{-6} at a specified sterilization dose

4 Definition of product families for dose setting, dose substantiation and sterilization dose auditing

4.1 General

The establishment of a sterilization dose and the carrying out of sterilization dose audits are activities that are part of process definition and maintaining process effectiveness (see ISO 11137-1). For these activities, product may be grouped into families. Definition of product families is based principally on the numbers and types of microorganisms on or in product (the bioburden), the type being indicative of the microorganism's resistance to radiation (see ISO 11137-1:2025, A.7.2 and ISO 11737-1). Variables such as density and product configuration within its packaging system are not considered in the establishment of these product families because they are not factors that influence bioburden.

NOTE 1 In using product families for establishing the sterilization dose and for carrying out sterilization dose audits, it is important to be aware of the reduction in the ability to detect an inadvertent change within the manufacturing process that influences the effectiveness of sterilization. Furthermore, with the use of a single product to represent the product family, it is possible that changes that occur in other members of the product family will not be detected. The effect of a reduction on ability to detect changes in other members of the product family is understood and a plan for maintaining product families is developed and implemented before proceeding.

NOTE 2 The product families outlined in [Clause 4](#) are based on their microbiological properties. In this document the concept of microbiological families is called product families.

4.2 Defining product families

4.2.1 The criteria for defining a product family shall be documented. Product shall be assessed against these criteria and the similarities between potential product family members considered. Consideration shall include all product- and sterile barrier system (SBS)-related variables that affect bioburden, including, but not limited to:

1. nature and sources of inputs, including, raw materials, components, and manufacturing process materials (e.g. water, cleaning solutions, machine fluids) and their ability to support microbial growth;
 - a) product design and size as it relates to product bioburden;
 - b) manufacturing processes, including level of automation versus manual operations and any washing or cleaning processes
 - c) manufacturing equipment;
 - d) manufacturing environment;
2. manufacturing location (see also [4.2.4](#)).

The outcome of the assessment and considerations shall be recorded.

4.2.2 Product shall only be included in a product family if it is demonstrated that the product- and SBS-related variables (see [4.2.1](#)) are similar and under control.

ISO/DIS 11137-2:2026(en)

4.2.3 To include product within a product family, it shall be determined that bioburden comprises similar numbers and types of microorganisms.

4.2.4 Inclusion of product from more than one manufacturing location in a product family shall be specifically justified and recorded. In addition to all elements of [4.2.1](#), consideration shall be given to:

- a) geographic or climatic differences, or both, between locations;
- b) any differences in the control of the manufacturing processes or environment.

4.3 Designation of product to represent a product family

4.3.1 Product to represent a product family

4.3.1.1 The number and types of microorganisms on or in product shall be used as the basis for selecting product to represent a product family.

4.3.1.2 A product family shall be represented by one of the following:

- a) the master product (see [4.3.2](#));
- b) an equivalent product (see [4.3.3](#));
- c) a simulated product (see [4.3.4](#)).

4.3.1.3 A formal, documented assessment shall be undertaken to decide which of the three potential representative products in [4.3.1.2](#) is appropriate. In this assessment, consideration shall be given to the following:

- a) number of microorganisms comprising the bioburden;
- b) types of microorganisms comprising the bioburden;
- c) environment in which the microorganisms occur;
- d) size of product;
- e) number of components;
- f) complexity of product;
- g) degree of automation during manufacture;
- h) manufacturing environment;
- i) SBS packaging process, materials, components and environment;
- j) production frequency and volume of production.

4.3.2 Master product

A member of a product family shall only be considered the master product if assessment (see [4.3.1.3](#)) indicates that the member presents a microbiological challenge to the sterilization process that is greater than that of all other product family members. The master product can have a different verification dose than other products that are given the same sterilization dose. In some situations, there can be several products within the product family, each of which could be considered as the master product. In such circumstances, any one of these products may be selected as the master product to represent the family, either

- a) at random; or